Cedars-Sinai Cancer | Strategic Alliance Partners

Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.